Prescription of nonselective <scp>NSAID</scp>s, coxibs and gastroprotective agents in the era of rofecoxib withdrawal ‐ a 617 400‐patient study

Valkhoff, Vera E.; Soest, Eva M. van; Masclee, Gwen; Bie, Sandra de; Mazzaglia, Giampiero; Molokhia, Mariam; Kuipers, Ernst J.; Sturkenboom, Miriam

doi:10.1111/apt.12028

Cited by 13 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over time, GPA prescribing rates have increased. For example, in a Dutch study, GPA prescribing with NSAIDs increased from 40% in 2001 to 70% in 2007, and in a study in three European countries, under‐use of GPA fell between 2000 and 2008 . That increase is evident taking all the studies together; those in the review to the end of 2005 reported a weighted mean GPA prescribing rate of 26%, while the 21 later studies published since 2005 reported 49%.…”

Section: Resultsmentioning

confidence: 98%

“…Italy 869 Appropriate protection in 34% Pasina et al 88 Analysis 93 Case-control study using information from 3 primary care databases for coxib treatment…”

Section: Lopez-pintor and Lumbreras 86mentioning

confidence: 99%

“…The Netherlands, U.K., Italy 14,146 > 80% cover in 49% taking coxib for ≥ 1 month Valkhoff et al 93 Population-based cohort study in 3 European countries possible explanation for the association between chronic severe pain and increased all-cause mortality is lack of mobility, and the removal of the cardioprotective benefits of active living, although this is no more than speculative.…”

Section: Lopez-pintor and Lumbreras 86mentioning

confidence: 99%

See 2 more Smart Citations

Nonsteroidal Anti‐Inflammatory Drugs, Gastroprotection, and Benefit–Risk

Moore

Derry

Simon³

et al. 2013

Pain Practice

View full text Add to dashboard Cite

BackgroundGastroprotective agents (GPA) substantially reduce morbidity and mortality with long-term nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin.ObjectiveTo evaluate efficacy of NSAIDs, protection against NSAID-induced gastrointestinal harm, and balance of benefit and risk.MethodsFree text searches of PubMed (December 2012) supplemented with “related citation” and “cited by” facilities on PubMed and Google Scholar for patient requirements, NSAID effectiveness, pain relief benefits, gastroprotective strategies, adherence to gastroprotection prescribing, and serious harm with NSAIDs and GPA.ResultsPatients want 50% reduction in pain intensity and improved fatigue, distress, and quality of life. Meta-analyses of NSAID trials in musculoskeletal conditions had bimodal responses with good pain relief or little. Number needed to treat (NNTs) for good pain relief were 3 to 9. Proton pump inhibitors (PPI) and high-dose histamine-2 receptor antagonists (H2RA) provided similar gastroprotection, with no conclusive evidence of greater PPI efficacy compared with high-dose H2RA. Prescriber adherence to guidance on use of GPA with NSAIDS was 49% in studies published since 2005; patient adherence was less than 100%. PPI use at higher doses over longer periods is associated with increased risk of serious adverse events, including fracture; no such evidence was found for H2RA. Patients with chronic conditions are more willing to accept risk of harm for successful treatment than their physicians.ConclusionGuidance on NSAIDs use should ensure that patients have a good level of pain relief and that gastroprotection is guaranteed for the NSAID delivering good pain relief. Fixed-dose combinations of NSAID plus GPA offer one solution.

show abstract

Section: Resultsmentioning

confidence: 98%

“…Italy 869 Appropriate protection in 34% Pasina et al 88 Analysis 93 Case-control study using information from 3 primary care databases for coxib treatment…”

Section: Lopez-pintor and Lumbreras 86mentioning

confidence: 99%

Section: Lopez-pintor and Lumbreras 86mentioning

confidence: 99%

See 1 more Smart Citation

Nonsteroidal Anti‐Inflammatory Drugs, Gastroprotection, and Benefit–Risk

Moore

Derry

Simon³

et al. 2013

Pain Practice

View full text Add to dashboard Cite

show abstract

“…3,4 It appears that the global situation on GPA co-prescription is improving, although the progress remains far from satisfactory.…”

Section: Acknowledgementmentioning

confidence: 99%

“…Among these, the Crohn's disease activity index, either in its original (CDAI) or abbreviated format (sCDAI), has proven valuable in monitoring disease progression and, to some extent, activity. 3,4 However, it is clear from the study of Lahiff and colleagues that CDAI, in any format, is of little value in distinguishing Crohn's disease from IBS. A cursory glance at the components of the CDAI reveals why; the weighting given to subjective variables: abdominal pain, well-being, and stool frequency.…”

Section: Acknowledgementmentioning

confidence: 99%